Federated Hermes Inc. Raises Stock Holdings in IQVIA Holdings Inc. $IQV

Federated Hermes Inc. lifted its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 4.0% during the second quarter, Holdings Channel reports. The fund owned 122,260 shares of the medical research company’s stock after purchasing an additional 4,701 shares during the quarter. Federated Hermes Inc.’s holdings in IQVIA were worth $19,267,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. Brighton Jones LLC grew its holdings in shares of IQVIA by 244.4% during the fourth quarter. Brighton Jones LLC now owns 3,575 shares of the medical research company’s stock worth $703,000 after buying an additional 2,537 shares in the last quarter. Atria Wealth Solutions Inc. boosted its position in IQVIA by 5.6% during the first quarter. Atria Wealth Solutions Inc. now owns 1,812 shares of the medical research company’s stock worth $319,000 after acquiring an additional 96 shares during the last quarter. Zions Bancorporation National Association UT purchased a new stake in IQVIA in the 1st quarter worth approximately $74,000. JPMorgan Chase & Co. raised its holdings in IQVIA by 45.7% in the 1st quarter. JPMorgan Chase & Co. now owns 2,545,014 shares of the medical research company’s stock valued at $448,686,000 after acquiring an additional 798,534 shares during the last quarter. Finally, Virtu Financial LLC lifted its stake in shares of IQVIA by 46.3% during the 1st quarter. Virtu Financial LLC now owns 6,480 shares of the medical research company’s stock worth $1,142,000 after purchasing an additional 2,050 shares during the period. Institutional investors and hedge funds own 89.62% of the company’s stock.

Analysts Set New Price Targets

IQV has been the subject of several analyst reports. Jefferies Financial Group upgraded IQVIA from a “hold” rating to a “buy” rating and upped their target price for the company from $195.00 to $225.00 in a research note on Tuesday, September 9th. Truist Financial reiterated a “buy” rating and set a $265.00 price objective (up from $235.00) on shares of IQVIA in a report on Wednesday, October 29th. Redburn Partners set a $214.00 target price on shares of IQVIA in a research report on Wednesday, September 3rd. Barclays upped their price target on shares of IQVIA from $185.00 to $200.00 and gave the stock an “equal weight” rating in a research report on Thursday, October 2nd. Finally, Stifel Nicolaus lifted their price target on shares of IQVIA from $234.00 to $254.00 and gave the company a “buy” rating in a report on Wednesday, October 29th. Two analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and six have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $241.44.

Insider Buying and Selling

In other IQVIA news, insider Eric Sherbet sold 4,000 shares of the company’s stock in a transaction that occurred on Wednesday, October 29th. The stock was sold at an average price of $219.70, for a total value of $878,800.00. Following the completion of the transaction, the insider owned 27,108 shares in the company, valued at $5,955,627.60. This represents a 12.86% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 1.60% of the company’s stock.

IQVIA Stock Performance

Shares of IQV stock opened at $218.20 on Wednesday. The company’s fifty day simple moving average is $215.90 and its 200-day simple moving average is $188.23. The company has a current ratio of 0.70, a quick ratio of 0.70 and a debt-to-equity ratio of 2.03. IQVIA Holdings Inc. has a 52 week low of $134.65 and a 52 week high of $234.29. The company has a market cap of $37.16 billion, a PE ratio of 29.93, a P/E/G ratio of 2.51 and a beta of 1.37.

IQVIA (NYSE:IQV) last released its quarterly earnings data on Tuesday, October 28th. The medical research company reported $3.00 EPS for the quarter, beating the consensus estimate of $2.98 by $0.02. The company had revenue of $4.10 billion for the quarter, compared to analyst estimates of $4.07 billion. IQVIA had a return on equity of 30.70% and a net margin of 8.07%.The firm’s revenue was up 5.2% compared to the same quarter last year. During the same period last year, the company posted $2.84 earnings per share. IQVIA has set its FY 2025 guidance at 11.850-11.950 EPS. As a group, equities research analysts anticipate that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.